Methanesulfonic acid imatinib polymorphic substance and medical combination thereof

A technology of imatinib mesylate and polymorphs, which is applied in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc., can solve the problems of inability to effectively remove mechanical impurities, unstable reproducibility, and poor product purity, etc. problem, to achieve the effect suitable for industrial scale preparation, good stability and high purity

Active Publication Date: 2012-12-12
NANJING CAVENDISH BIO ENG TECH +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These existing methods have a series of shortcomings such as cumbersome process, unstable reproducibility, technical solutions that cannot ensure the effective removal of mecha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methanesulfonic acid imatinib polymorphic substance and medical combination thereof
  • Methanesulfonic acid imatinib polymorphic substance and medical combination thereof
  • Methanesulfonic acid imatinib polymorphic substance and medical combination thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Example 1 Preparation of crude imatinib mesylate

[0102] Imatinib (2Kg), methanesulfonic acid (390g) and acetone (20L) were added to the reaction flask, and the temperature was raised to reflux for 2.5 hours while stirring. It was cooled to room temperature, and stirred for 3 hours to crystallize. The filter cake was collected by suction filtration and dried under reduced pressure at 70°C to a constant weight to obtain 2.2 Kg of crude imatinib mesylate. The yield was 92.1%.

[0103] Purity: 98.7%.

Embodiment 2

[0104] Example 2 Preparation of Polymorph III

[0105] Preparation of imatinib free base

[0106] The crude imatinib mesylate (1.5Kg) obtained in Example 1 was added to water (15L), the temperature was raised to 60°C, and the mixture was stirred and dissolved. Suction to remove impurities. The filtrate was cooled to room temperature, and acetone (4.5L) was added with stirring. Sodium bicarbonate (214g) was added and crystallized at room temperature for 3 hours. After suction filtration, the filter cake was washed with water and dried to a constant weight to obtain 1.17Kg of imatinib. Yield: 92.9%.

[0107] Preparation of imatinib mesylate

[0108] The imatinib (80g), methanesulfonic acid (15.6g) and methyl tert-butyl ether (800ml) obtained above were added to the reaction flask, and the temperature was raised to reflux for 2 hours under stirring. It was cooled to room temperature and stirred for 1 hour to crystallize. The filter cake was collected by suction filtration and dried...

Embodiment 3

[0111] Example 3 Preparation of polymorph III

[0112] According to the existing method, we use different crystal forms of imatinib mesylate prepared by different processes as raw materials, and the data table of the preparation of polymorph III according to the scheme of Example 2 is as follows:

[0113]

[0114] It can be seen from the above test data that any crystal form of crude imatinib mesylate can be transformed into the crystal form of the present invention. At the same time, impurities can be effectively removed to obtain high purity imatinib mesylate up to 99.9%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses methanesulfonic acid imatinib polymorphic substance III. In addition, the invention further discloses a preparation and medical combination of the methanesulfonic acid imatinib polymorphic substance III.

Description

Technical field [0001] The present invention relates to a polymorph of a pharmaceutical compound, more specifically, to a novel polymorph of imatinib mesylate. In addition, the present invention also relates to a method for preparing the polymorph and the same Pharmaceutical composition. Background technique [0002] Imatinib mesylate, a tyrosinase inhibitor, is used to treat gastrointestinal stromal tumors (GISTs). Its chemical name is 4-(4-methylpiperazine-1-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidine-2-amino]phenyl]-benzene Formamide methanesulfonate has the following chemical structure: [0003] [0004] Chinese Patent Application-Application No. 98807303.X (hereinafter referred to as Patent Application No. 303) discloses two polymorphs α and β of imatinib mesylate; among them, α crystal form is characterized by hygroscopicity and fluidity. Needle-like crystals with poor properties, the typical XRPD pattern shows that the α-type is in 4.9, 10.5, 14.9, 16.5, 17.7, 18.1, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/04A61K31/506A61P35/00
Inventor 严荣杨浩许永翔
Owner NANJING CAVENDISH BIO ENG TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap